Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous Dendritic Cell / Tumor Antigen (ADCTA-SSI-G1) for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM): A Multi-center, Open-label, Randomized Phase III Clinical Trial

NCT04277221 is registered in ClinicalTrials.gov with Safe Save Medical Cell Sciences & Technology Co.,Ltd. as lead sponsor.

NCT NCT04277221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04277221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous Dendritic Cell / Tumor Antigen (ADCTA-SSI-G1) for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM): A Multi-center, Open-label, Randomized Phase III Clinical Trial
Lead sponsor
Safe Save Medical Cell Sciences & Technology Co.,Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
September 19, 2019
Completion date
December 31, 2022
Enrollment
118 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme